Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Keros Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Keros Therapeutics, Inc.

KROS

Keros Therapeutics, Inc.

About Keros Therapeutics, Inc.

Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel TGF-β pathway therapeutics for disorders affecting blood, bone, muscle, and cardiovascular tissues. Its key products target pulmonary arterial hypertension, neuromuscular diseases, and hematologic conditions like MDS and myelofibrosis. The company's approach leverages proprietary protein therapeutics to modulate tissue growth, repair, and maintenance, aiming to address unmet medical needs with potentially disease-modifying treatments.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Keros Therapeutics, Inc.

1
1
Keros Therapeutics, Inc. Keros Therapeutics Reports Significant Revenue Decline and Net Loss in Q1 2026

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Keros Therapeutics, Inc. Keros Therapeutics Reports $87M Net Income for Fiscal Year 2025 Driven by Takeda Licensing Agreement

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Keros Therapeutics, Inc. Keros Therapeutics Reports $14.3M Revenue and $7.3M Net Loss for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Keros Therapeutics, Inc. Keros Therapeutics Reports $229.4 Million Revenue for First Half of 2025, Plans $375 Million Capital Return

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Keros Therapeutics, Inc. Keros Therapeutics Reports $211.2 Million Revenue and $148.5 Million Net Income in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Keros Therapeutics, Inc. Keros Therapeutics Reports Revenue Growth, Increased Operating Expenses, and Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments